Genprex, Inc. (GNPX) is a leading clinical-stage biopharmaceutical company. The company is engaged in the development of disease-fighting genes for the treatment of cancer and diabetes patients. One of the company’s lead drug candidates is REQORSA being assessed for the treatment of non-small cell lung cancer. The company is also developing GPX-002 as the genetic therapy method for diabetes. Another product candidate is ONCOPREX which is a nanoparticles delivery platform.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
The price of GNPX stock during the regular trading on January 6, 2022, was $2.21 with a 2.64% drop. At last check in the premarket on January 7, 2022, the stock surged by 5.88%.
GNPX: Events and Happenings
On January 5, 2022, GNPX reported that the company’s Executives will participate in the following investor and healthcare conferences. Virtual HC Wainwright BIOCONNECT 2022 Conference which will be held on January 10-13, Biotech Showcase 2022 being held on January 10-13, Virtual Precision: Lung Cancer World R&D Summit on 25-26 January, and CEO Roadshow on January 26, 2022.
On January 4, 2022, GNPX reported about the expansion of its research and development pipeline related to cancer for the inclusion of small cell lung cancer as an extra disease indication for REQORSA. SCLC represented up to 10-15% of the lung cancer portfolio, whereas REQORSA’s preliminary target indication of NSCLC represented up to 84% of the lung cancer portfolio.
On January 3, 2022, GNPX reported about the grant of Fast Track Designation by FDA for its lead product REQORSA, along with Keytruda of Merck & Company. The company expected to start its Acclaim-2 clinical trial. Earlier, GNPX received its initial FTD for REQORSA along with Tagrisso of AstraZeneca PLC.
GNPX: Key Financials
On November 15, 2021, GNPX reported its financial results for the third quarter ended September 30, 2021. Some of the important highlights are as follows.
Net Loss per Share
Basic and diluted net loss per share for the third quarter of 2021 was $3.4 million or $0.07 per share as compared to the net loss for the same period of 2020 when it was $2.7 million or $0.07 per share.
Total Current Assets
Total current assets reported for the company for Q3 2021 were $45.6 million.
Conclusion
GNPX stock is 47% up to as compared to the last month. Although the stock tumbled in the regular trading it bounced back in the current premarket session. The surge in stock price is possibly associated with the company’s announcement regarding its participation in investor and healthcare conferences. The analysts are optimistic that the company will maintain its current track record and will attract potential investors in the future.
